Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Completed · Phase 3 · Has a placebo group

Conditions studied: Children and Adolescent With Type 2 Diabetes

In brief

The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes

Key facts

Study ID

NCT01554618

Run by

AstraZeneca

People needed

84

Starts

2011-12-02

Expected to finish

2021-05-05

Last updated by the study team

2021-11-30

Who can join

Age: 10 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Los Angeles, California, United States
• Research Site — New Haven, Connecticut, United States
• Research Site — Iowa City, Iowa, United States
• Research Site — Kansas City, Kansas, United States
• Research Site — Louisville, Kentucky, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — Jackson, Mississippi, United States
• Research Site — Buffalo, New York, United States
• Research Site — Chapel Hill, North Carolina, United States
• Research Site — Charlotte, North Carolina, United States
• Research Site — Cleveland, Ohio, United States
• Research Site — Oklahoma City, Oklahoma, United States
• Research Site — Rapid City, South Dakota, United States
• Research Site — Nashville, Tennessee, United States
• Research Site — Dallas, Texas, United States
• Research Site — Houston, Texas, United States
• Research Site — Pleven, Bulgaria
• Research Site — Sevlievo, Bulgaria
• Research Site — Baja, Hungary
• Research Site — Budapest, Hungary
• Research Site — Budapest, Hungary
• Research Site — Budapest, Hungary
• Research Site — Szeged, Hungary
• Research Site — Beersheba, Israel
• Research Site — Haifa, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.